Your browser doesn't support javascript.
loading
Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
Kartolo, Adi; Kassouf, Wassim; Vera-Badillo, Francisco E.
Afiliación
  • Kartolo A; Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, Canada.
  • Kassouf W; Division of Urology, Department of Surgery, McGill University Health Center, Montreal, Canada.
  • Vera-Badillo FE; Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, Canada. Electronic address: francisco.verabadillo@kingstonhsc.ca.
Eur Urol ; 80(6): 679-681, 2021 12.
Article en En | MEDLINE | ID: mdl-34366212
ABSTRACT
We discuss results from the Checkmate-274 and IMvigor010 trials on adjuvant immune checkpoint inhibitor (ICI) therapy in muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC), and conclude that adjuvant ICI (nivolumab but not atezolizumab) should be considered for patients with resected high-risk MIBC, especially for those who have received NAC.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Inhibidores de Puntos de Control Inmunológico Límite: Female / Humans / Male Idioma: En Revista: Eur Urol Año: 2021 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Inhibidores de Puntos de Control Inmunológico Límite: Female / Humans / Male Idioma: En Revista: Eur Urol Año: 2021 Tipo del documento: Article País de afiliación: Canadá